Exploring the NRF2 pathway in FRDA and its modulation by “old” and “new” compounds may help to better understand the FRDA pathogenesis and contribute to develop innovative therapies, also taking into account the emerging “mechanism-based” approach to diseases that was recently proposed by Cuadrado et al. [2]. This evidence concerns the gene NFE2L2 and Friedreich ataxia.